Published in Cancer Epidemiol Biomarkers Prev on September 17, 2013
Diet quality and survival after ovarian cancer: results from the Women's Health Initiative. J Natl Cancer Inst (2014) 0.85
The effect of neighborhood-level socioeconomic status on racial differences in ovarian cancer treatment in a population-based analysis in Chicago. Gynecol Oncol (2014) 0.79
Depression and Oropharynx Cancer Outcome. Psychosom Med (2016) 0.77
Treatment ethics, quality of life and health economics in the management of hematopoietic malignancies in older patients. Bone Marrow Transplant (2015) 0.76
Impact of the AYA HOPE Comorbidity Index on Assessing Health Care Service Needs and Health Status among Adolescents and Young Adults with Cancer. Cancer Epidemiol Biomarkers Prev (2015) 0.75
Moonshots and metastatic disease: the need for a multi-faceted approach when studying atypical responses. NPJ Breast Cancer (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol (2008) 3.90
Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer (2009) 3.79
A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg (2006) 2.97
One year pre-post intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients. Brain Behav Immun (2007) 2.94
Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer (2007) 2.64
Changes in job strain in relation to changes in physiological state. A longitudinal study. Scand J Work Environ Health (1988) 2.57
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res (2003) 2.50
Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol (2005) 2.18
Cancer and comorbidity: redefining chronic diseases. Cancer (2000) 2.12
Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol (2005) 2.11
Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol (2007) 1.92
Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res (2008) 1.83
Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks. Arch Gen Psychiatry (1998) 1.70
Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol (2012) 1.65
Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer (2005) 1.58
Neuroendocrine modulation of cancer progression. Brain Behav Immun (2008) 1.51
Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol (2003) 1.48
Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol (2010) 1.47
Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res (2008) 1.46
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol (2009) 1.45
Venous thromboembolism in ovarian cancer. Gynecol Oncol (2007) 1.42
Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol (2003) 1.40
Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol (2008) 1.37
Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol (2009) 1.35
The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study. BMC Cancer (2008) 1.31
Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Br J Cancer (2004) 1.29
The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol (2005) 1.21
Chronic mental stress is a cause of essential hypertension: presence of biological markers of stress. Clin Exp Pharmacol Physiol (2008) 1.21
Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer (2008) 1.06
Physiologic changes in men whose jobs were abolished. J Psychosom Res (1974) 1.04
Prognostic value of clinical variables in ovarian cancer. J Clin Epidemiol (1997) 0.91
Cardiorenal epinephrine kinetics: evidence for neuronal release in the human heart. Am J Physiol (1997) 0.77
Statins in preparation for chemotherapy: "do these medications help your fitness for battle?". J Am Coll Cardiol (2012) 0.76
Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Ann Surg Oncol (2006) 0.76
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer (2006) 4.27
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Retraction of an interpretation. Lancet (2004) 3.55
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res (2010) 3.36
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol (2006) 3.34
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation (2004) 2.73
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol (2005) 2.72
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res (2003) 2.50
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res (2006) 2.32
Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A (2010) 2.31
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J Card Fail (2009) 2.10
Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. J Clin Oncol (2014) 2.05
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Platelets increase the proliferation of ovarian cancer cells. Blood (2012) 1.97
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol (2006) 1.93
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res (2007) 1.90
Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol (2010) 1.89
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res (2011) 1.84
Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol (2013) 1.81
Axillary artery cannulation in surgery for acute or subacute ascending aortic dissections. Ann Thorac Surg (2010) 1.80
EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res (2004) 1.80
Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer (2005) 1.79
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res (2008) 1.77
Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res (2009) 1.73
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther (2010) 1.71
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res (2007) 1.68
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res (2007) 1.66
Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun (2008) 1.66
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol (2011) 1.65
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res (2005) 1.63
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol (2006) 1.63
Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62